UK Markets open in 1 hr 32 mins

SCANS: The FAANG of The Roaring 20s

Daniel Laboe

We are just entering the roaring 20s, and it is time to readjust your portfolio for the next decade. FAANG had been the biggest tech driver for the past 10 years. Their exponential returns may be exhausted, and I think its time to look for next decade-defining equities.

When assessing “market-shifting” companies, you need to look for firms with an exciting product offering characterized by longevity and a substantial addressable market. Not to mention savvy management teams that can navigate through both the best and worst times

I have chosen my own acronym of stocks that I believe could redefine the roaring 20s: “SCANS.” This acronym includes Sea Limited SE, CRISPR CRSP, Alibaba BABA, Nvidia NVDA, and Splunk SPLK.

My article SCANS: The FAANG of the Roaring 20s gives a more detailed analysis of my pick and would make an excellent supplementary read to this video.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Alibaba Group Holding Limited (BABA) : Free Stock Analysis Report
 
Splunk Inc. (SPLK) : Free Stock Analysis Report
 
Sea Limited Sponsored ADR (SE) : Free Stock Analysis Report
 
NVIDIA Corporation (NVDA) : Free Stock Analysis Report
 
CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research